Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 5, 2005, Pages 433-438

  Kirstein, Mark N ^a,b   Panetta, John C ^a   Gajjar, Amar ^a   Nair, Geeta ^a   Iacono, Lisa C ^a   Freeman III, Burgess B ^a   Stewart, Clinton F ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Children; D optimal sampling; Monte Carlo simulation; MTIC; Temozolomide

Indexed keywords

DRUG METABOLITE; METHYLTRIAZENE; ONDANSETRON; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; MONTE CARLO METHOD; PREDICTION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; DACARBAZINE; HUMANS; INFANT; METABOLIC CLEARANCE RATE; MONTE CARLO METHOD;

EID: 17644420332     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0896-9     Document Type: Article

References (19)

1. Brandes AA, Pasetto LM, Monfardini S (2000) New drugs in recurrent high grade gliomas. Anticancer Res 20:1913
2. Prados MD (2000) Future directions in the treatment of malignant gliomas with temozolomide. Semin Oncol 27:41
3. 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5:309
4. Newlands ES, Blackledge GRP, Slack JA, Rustin GJS, Smith DB, Stuart NSA, Quarterman CP, Hofman R, Stevens MFG, Brampton MH, Gibson AC (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65:287
5. Reid JM, Stevens DC, Rubin J, Ames MM (1997) Pharmacokinetics of 3-methyl-(triazen-l-yl)imidazole-4-carboximide following the administration of temozolomide to patients with advanced cancer. Clin Cancer Res 3:2393
6. Reed MD (1999) Optimal sampling theory: an overview of its application to pharmacokinetic studies in infants and children. Pediatrics 104:627
7. Panetta JC, Iacono LC, Adamson PC, Stewart CF (2003) The importance of pharmacokinetic limited sampling models for childhood cancer drug development. Clin Cancer Res 9:5068
8. Estlin EJ, Lashford L, Ablett S, Price L, Gowing R, Gholkar A, Kohler J, Lewis IJ, Morland B, Pinkerton CR, Stevens MC, Mott M, Stevens R, Newell DR, Walker D, Dicks-Mireaux C, McDowell H, Reidenberg P, Statkevich P, Marco A, Batra V, Dugan M, Pearson AD (1998) Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer 78:652
9. Panetta JC, Kirstein MN, Gajjar A, Nair G, Fouladi M, Heideman RL, Wilkinson M, Stewart CF (2003) Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemother Pharmacol 52:435
10. Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet, D, Griffiths PD, Doz F, Ironside J, Robson K, Hobson R, Dugan M, Pearson AD, Vassal G, Frappaz D (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 20:4684
11. Hammond LA, Eckardt JR, Baker SD, Eckhardt SG, Dugan M, Forral K, Reidenberg P, Statkevich P, Weiss GR, Rinaldi DA, Von Hoff DD, Rowinsky EK (1999) Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 17:2604
12. Jen JF, Cutler DL, Pai SM, Batra VK, Affrime MB, Zambas DN, Heft S, Hajian G (2000) Population pharmacokinetics of temozolomide in cancer patients. Pharm Res 17:1284
13. Panetta JC, Kirstein MN, Gajjar AJ, Nair G, Fouladi M, Stewart CF (2003) A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas. Math Biosci 186:29
14. Steimer JL, Mallet A, Golmard JL, Boisvieux JF (1984) Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev 15:265
15. D'Argenio DZ, Schumitzky A (1990) ADAPT II user's guide. Biomedical Simulation Resource, University of Southern California, Los Angeles
16. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker, New York
17. D'Argenio DZ (1981) Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 9:739
18. Panetta JC, Wilkinson M, Pui C-H, Relling MV (2002) Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia. J Pharmacokinet Pharmacodyn 29:171
19. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503